Bone Glue Market to surpass US$ 4.30 Bn by 2031

Global Bone Glue Market is Estimated to Witness High Growth Owing to the Rising Number of Sports Injuries and Increasing Adoption of Mini-Invasive Surgeries

The Global Bone Glue Market is estimated to be valued at USD 2.91 Bn in 2024, exhibiting a CAGR of 5.7% over the forecast period (2024-2031). Bone glue holds immense potential for replacing metal plates and screws for fixation of fractures. Furthermore, increasing adoption of bone glue as an alternative to bone grafting is anticipated to fuel market growth during the forecast period.

Market Dynamics:

The global bone glue market is driven by rising number of sports injuries and increasing adoption of mini-invasive surgeries. According to the Centers for Disease Control and Prevention (CDC), over 3.5 million sports injuries occur each year in the United States requiring medical treatment or restricted activity. Sports injuries, especially bone fractures, have augmented the demand for bone glue in orthopedic applications. Moreover, bone glue allows surgeons to carry out mini-invasive procedures reducing surgical wounds and recovery time. This has stimulated its adoption over metal plates and screws in several sports-related reconstructive surgeries. In addition, growing geriatric population suffering from osteoporosis has upsurged fragility fractures propelling the need for durable bone bonding alternatives like bone glue. The availability of technologically advanced bone glues offering high bonding strength in wet conditions and at physiological temperatures further enhances their application in complex surgical procedures, including orthopedic, craniofacial, and dental surgeries, where traditional adhesives often fall short in performance.

Growing Prevalence of Orthopedic Disorders

One of the primary drivers fueling the growth of the global bone glue market is the rising incidence of orthopedic disorders globally. Bone glue products are widely used during orthopedic surgeries and procedures to fix fractured or damaged bones. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, over 30 million Americans suffer from osteoarthritis. Additionally, around 1.6 million Americans experience hip fractures each year. Such a high prevalence of orthopedic conditions is increasing the demand for bone glues during surgical repairs and replacements, thereby augmenting market growth.

Advantages Over Traditional Fixation Methods

Another key factor propelling the bone glue market is the various advantages bone glues provide over traditional bone fixation methods like plates, screws and nails. Bone glues offer minimal invasiveness, faster recovery times for patients, enhanced stability, and stronger fixation between bones. They enable surgeons to achieve proper alignment of fractures with less soft tissue stripping compared to metal implants. Bone glues also eliminate the need for a second surgery to remove fixation devices. Owing to these benefits, bone glues are gaining popularity among medical professionals and patients, which is positively impacting the demand.

Risk of Disease Transmission

One of the major constraints affecting the bone glue market is the potential risk of infection or disease transmission associated with the use of bone glues derived from humans or animals. Such glues derived from donated tissues can transmit diseases like HIV and hepatitis. Stringent regulations have been imposed on procurement and processing of donated tissues to minimize these risks. However, the processes involved increase production costs and complexities. This acts as a hindrance to market growth.

Availability of Alternative Treatment Options

Availability of alternative treatment options is another challenge faced by market players. Alternatives like bone grafts and synthetic bone substitutes are available for bone fixation. While synthetic bone substitutes avoid disease transmission risks, bone grafts provide osteoinductive and osteoconductive properties for better healing. Additionally, traditional fixation methods continue to be popular and effective for certain fractures. Presence of these substitutes poses a threat to the bone glue market by limiting its adoption.

Emerging Economies in Asia Pacific

The bone glue market sees lucrative opportunities in emerging countries of Asia Pacific owing to their large population bases and improving healthcare expenditures. According to the WHO, by 2050, over 60% of the world's elderly population will reside in Asia Pacific. This raises the risk of osteoporosis and orthopedic issues in these regions. At the same time, healthcare domains in Asian countries like India, China, and South Korea are witnessing higher investments. This is increasing affordability and acceptance of advanced treatment options like bone glues. Market players like Stryker can gain sizeable revenues by tapping into Asia Pacific's potential.

New Product Innovation and Developments

Continuous innovations are being made to bone glues to further strengthen their value proposition. Companies are engaged in developing bone glues that exhibit more effective fixation abilities, require shorter clamping or fixation times and allow for weight bearing immediately after surgery. Some players are exploring recombinant DNA technology to manufacture human-compatible synthetic bone glues. Such product advancements will help address existing challenges and expand the applicability of bone glues. This provides lucrative opportunities for companies to launch new and improved bone glue formulations in the market.

Link - https://www.coherentmarketinsights.com/market-insight/bone-glue-market-242

Key Developments:

• On December 11, 2024, RevBio, Inc., a clinical-stage medical device company, announced USFDA approval to expand its clinical trial for the immediate fixation of cranial flaps using TETRANITE, its bone adhesive biomaterial. Additionally, the company secured reimbursement coverage from the Centers for Medicare and Medicaid Services (CMS) for TETRANITE as an alternative to metal plates and screws.
• In October 2023, RevBio, Inc., a clinical-stage medical device company, was awarded a grant of up to US$ 3.4 million over three years (1SB1AG085803-01) from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), under its Commercialization Readiness Program. The grant will fund the completion of late-stage product development and a clinical trial to evaluate the product's safety and efficacy compared to the current standard of care.
• In December 2021, icotec ag, a manufacturer of Carbon/PEEK implants, partnered with G-21, a specialist in medical and pharmaceutical products, to distribute G-21’s bone cements alongside icotec's VADER Pedicle Screw System in the U.S. The VADER Pedicle System is designed to restore spinal column integrity in patients with advanced-stage thoracic or lumbar spine tumors who have a limited life expectancy that precludes achieving fusion before oncological treatment.
• In November 2021, a study published in Frontiers in Bioengineering and Biotechnology, a multidisciplinary journal, investigated the use of a biomimetic bio-adhesive for bone repair, from incision to healing. The OsStic adhesive seamlessly integrated with local bone biology in a murine bone core model, showing no inflammation or adverse tissue effects. By day 42, the cortical and cancellous bone compartments had recovered approximately 50% and 70% of their original quality and quantity, respectively, as the adhesive layer was replaced by bone multicellular units during healing.

Key Players:

Medtronic, Johnson & Johnson, Stryker, B. Braun Melsungen AG, Zimmer Biomet, Smith & Nephew, Baxter International, Integra LifeSciences, CryoLife, Heraeus Medical, DJO Global, Aesculap, Arthrex, Exactech, and Cardinal Health